ArticleNucleic acids research2026
TPDdb: the comprehensive database of targeted protein degrader.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation.Pharmaceutics · 2026Review
- Mapping Scientific Landscapes and Therapeutic Innovations of Targeted Protein Degradation: A Scientometric Review.Pharmaceutics · 2026Review
- The 2026 Nucleic Acids Research database issue and the online molecular biology database collection.Nucleic acids research · 2026Article
- Advancing PROTAC Discovery Through Artificial Intelligence: Opportunities, Challenges, and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Targeted protein degraders (TPDs) have emerged in the past decade as a new drug modality of transformative paradigm, offering a powerful strategy to catalytically remove disease-relevant proteins, especially those long considered as "undruggable." With the rapid advancement in this direction, there is increasing demand for a database describing TPDs. Herein, a comprehensive database of TPDs, titled TPDdb, was therefore developed. TPDdb is unique in (i) covering the largest amount of TPDs among existing databases (6002 Molecular Glues, 22 183 PROTACs, 249 LYTACs, 169 ATTECs, 29 AUTOTACs, and 23 AUTACs targeting 580 proteins of interest and associated with 274 diseases) with their structural and physicochemical properties offered; (ii) describing 27 796 activities (IC50, DC50, Dmax, etc.) for all collected TPDs related to 201 cell lines; and (iii) providing the structures of TPDs, proteins of interest, ligase, and experimentally determined ternary complexes. TPDdb is now accessible at https://idrblab.org/TPDdb/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.